Welcome to our dedicated page for Chemours Co SEC filings (Ticker: CC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Chemours manages titanium dioxide pricing cycles, PFAS litigation reserves, or refrigerant phase-down costs can feel like wading through hundreds of pages of SEC text. Our platform tackles that complexity head-on. The moment a Chemours 8-K material events explained notice or Chemours insider trading Form 4 transactions hits EDGAR, Stock Titan’s AI parses it, flags the environmental, legal, and segment earnings details investors hunt for, and delivers a clear summary you can read in minutes.
Need the latest Chemours quarterly earnings report 10-Q filing? We link the PDF, highlight Ti-Pure™ pricing disclosures, and translate footnotes into plain English. Curious about executive moves? Real-time alerts on Chemours Form 4 insider transactions real-time show exactly when directors buy or sell—critical context before pigment price announcements. Our coverage spans every form: the annual report—Chemours annual report 10-K simplified—with AI-driven red-line comparisons, the proxy statement outlining Chemours proxy statement executive compensation, down to niche S-3 shelf registrations.
Professionals use these insights to: 1) monitor litigation accrual swings quarter-to-quarter, 2) compare segment EBITDA trends without digging through exhibits, 3) follow Chemours executive stock transactions Form 4 ahead of earnings. Whether you ask “understanding Chemours SEC documents with AI” or search “Chemours earnings report filing analysis,” this page delivers concise answers, complete filings, and expert context—all continuously updated so you never miss a disclosure that moves the stock.
On 08/01/2025, Chemours (CC) President & CEO Denise Dignam filed a Form 4 disclosing an automatic share withholding (Transaction Code F) tied to vested restricted stock units.
- Shares withheld: 466 common shares at $11.50, executed solely to satisfy tax obligations; no open-market sale occurred and the trade is Rule 16b-3 exempt.
- Remaining ownership: 187,478.1549 shares held directly, meaning the transaction reduced her stake by roughly 0.25%.
- Insider role: Dignam serves as both President & CEO and Director, maintaining substantial equity alignment with investors.
The event is routine, immaterial to Chemours’ capital structure and does not signal a change in insider sentiment.
Chemours Company (CC) Form 4 filing – 8/1/2025
President, Thermal & Specialized Solutions, Joseph T. Martinko reported an automatic share disposition coded “F,” indicating 649 common shares were withheld by the company at $11.50 to cover taxes triggered by the vesting of restricted stock units (RSUs) and related dividend-equivalent units. No shares were sold on the open market; therefore, the transaction is exempt under Rule 16b-3.
- Post-transaction beneficial ownership: 30,936.6241 shares (direct)
- Insider role: Executive officer – President, Thermal & Specialized Solutions
- Purpose: Tax withholding; routine administrative event
Given the small share count (<0.1% of total ownership) and non-cash nature, the filing is considered operationally routine with minimal investment impact.
Chemours (CC) posted a sharp swing to loss in Q2-25. Net sales rose 3.9% YoY to $1.615 billion, but gross profit contracted 9.7% to $278 million and SG&A ballooned to $437 million (vs. $154 million), driving a GAAP net loss of $380 million (-$2.54 per diluted share) versus $60 million profit a year ago. Six-month sales improved 2.3% to $2.983 billion, yet the company recorded a H1-25 loss of $384 million (-$2.56 per share) against $113 million income in H1-24.
Cash from operations was a modest -$19 million, far better than the -$910 million outflow reported in the prior-year period, helped by smaller working-capital drains. Free cash flow remained negative as Chemours spent $127 million on capex. Cash and equivalents fell to $502 million from $713 million at year-end, while long-term debt inched up to $4.102 billion. Total equity shrank to $239 million, reflecting the loss and a dividend cut to $0.0875 per share (vs. $0.25 last year).
The company cites $954 million unused capacity on its revolving credit facility and believes liquidity is adequate through August 2026, but warns that adverse outcomes in PFAS and other legal/environmental matters could be material. Management revised prior-period financials for presentation errors; impacts were immaterial.
Settlement overview. On 3 Aug 2025 Chemours, DuPont and Corteva entered a proposed Judicial Consent Order with New Jersey that would resolve all state PFAS and legacy-site contamination claims. The Companies will pay an aggregate $875 million in cash to the state, spread over 25 years starting no earlier than 1 Jan 2026; the total present value, discounted at 8%, is about $500 million. Chemours will fund 50%, DuPont 35.5% and Corteva 14.5%.
Funding & security. Site-specific Remediation Funding Sources will be backed by surety bonds, and DuPont/Corteva will establish a separate Reserve Fund (71%/29%) for future remediation. A parallel Insurance Proceeds MOU lets DuPont and Corteva purchase Chemours’ rights to $150 million of potential PFAS insurance recoveries; after repayment plus a fee, further proceeds are split 50/50. Chemours expects existing escrowed cash and the assigned insurance proceeds to cover its settlement payments through at least 2030.
Next steps & impact. The deal needs public notice, comment and court approval and contains no admission of liability. It reduces legal uncertainty and staggers cash outflows, but long-term PFAS exposure, possible additional remediation costs and regulatory shifts remain key risks, as outlined in the forward-looking-statement section.
FAQ
What is the current stock price of Chemours Co (CC)?
What is the market cap of Chemours Co (CC)?
